Skip to main navigation Skip to search Skip to main content

Fluoxetine and fractures after stroke: An individual patient data meta-analysis of three large randomized controlled trials of fluoxetine for stroke recovery

  • Gillian Mead
  • , Catriona Graham
  • , Erik Lundström
  • , Graeme J. Hankey
  • , Maree L. Hackett
  • , Laurent Billot
  • , Per Näsman
  • , John Forbes
  • , Martin Dennis
  • University of Edinburgh
  • Uppsala University
  • University of Western Australia
  • Perron Institute for Neurological and Translational Science
  • The George Institute for Global Health
  • University of New South Wales
  • University of Central Lancashire
  • KTH Royal Institute of Technology

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Observational studies have shown that selective serotonin reuptake inhibitors are associated with an increased risk of bone fractures, but the association can be confounded by indication and other sources of systematic bias that can be minimized in randomized controlled trials (RCTs). Aim: Our aim was to report the rate, site, context, and predictors of fractures after stroke, and whether the fractures modified the effect of fluoxetine on modified Rankin scale (mRS) at 6 months in an individual patient data meta-analysis of 5907 patients enrolled in three RCTs of fluoxetine (20 mg for 6 months) for stroke recovery. Methods: We classified fractures by treatment allocation, site (and thus likelihood of osteoporosis), and context, then performed multivariable analyses to explore the independent predictors of fractures. We explored whether the trend toward a poorer mRS at 6 months was explained by a fracture excess. Risk of bias was assessed using GRADE. Results: Among 5907 patients randomized at a mean of 6.6 days (SD 3.6) post-stroke onset and followed for 6 months, the number of fractures at 6 months was 93 (3.15%) in the fluoxetine group versus 41 (1.39%) in the control group (difference 1.76, 95% CI 0.10–2.51). However, 128 patients with fractures were suitable for further analyses. Of these, 102 (80%) were in sites typically affected by osteoporosis; 115 (90%) were associated with falls and 1 (1%) with a seizure. Independent fracture risk factors were female sex (hazard ratio (HR) 1.96; 95% CI 1.37–2.81, p = 0.0002), age > 70 years (HR 2.30, 95% CI 1.52–3.49, p < 0.001), previous fractures (HR 0.63 for no previous fractures, 95% CI 0.42–0.94, p = 0.0227), and randomized treatment (fluoxetine) (HR 2.39; 95% CI 1.64–3.49, p < 0.001). The common odds ratio for the effect of fluoxetine on mRS at 6 months was unchanged after excluding fracture patients. Risk of bias was high for imprecision. Conclusion: Fractures were more common in the fluoxetine group but the absolute risk of fractures was small and risk estimates were imprecise. Most fractures occurred with a fall, and in osteoporotic locations. Fractures did not modify the effect of fluoxetine on functional outcome.

Original languageEnglish
Pages (from-to)540-549
Number of pages10
JournalInternational Journal of Stroke
Volume20
Issue number5
DOIs
Publication statusPublished - Jun 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • bone fractures
  • falls
  • fluoxetine
  • Stroke

Fingerprint

Dive into the research topics of 'Fluoxetine and fractures after stroke: An individual patient data meta-analysis of three large randomized controlled trials of fluoxetine for stroke recovery'. Together they form a unique fingerprint.

Cite this